<DOC>
	<DOCNO>NCT01258634</DOCNO>
	<brief_summary>This pilot study allow investigator collect data relate early potentially accurate response assessment use chemotherapy protocol eliminate methotrexate maximize dose intensity doxorubicin . The pilot data use seek funding fully address hypothesis multi-institutional , Phase II Phase III trial . The primary secondary objective follow : Primary : 1 . To evaluate feasibility potential usefulness measure early change tumor metabolic activity , assess Fludeoxyglucose-Positron Emission Tomography ( FDG-PET ) image alkaline phosphatase activity , early predictor histological response rate 12 week osteosarcoma patient . 2 . To explore whether histological response assess computer algorithm use virtual microscopic image pathology material , whether quantify necrosis way correlate microscope slide-based review . Secondary : 1 . To gather pilot data histological response rate , 3-year event-free survival , toxicity child young adult resectable osteosarcoma treat use chemotherapy regimen alternate course doxorubicin/cisplatin ( DC ) doxorubicin/ifosfamide/etoposide ( IDE ) . All patient receive 4 course preoperative chemotherapy course . With exception high-dose methotrexate , give weekly , preoperative postoperative chemotherapy course plan begin every 21 day . Patients good histological response ( patient &gt; 90 % tumor necrosis time definitive resection ) receive three postoperative chemotherapy course . The 1st consist doxorubicin , dexrazoxane , cisplatin Granulocyte-Colony Stimulating Factor ( G-CSF ) ( Polyethylene Glycol filgrastim ) . The 2nd course consist doxorubicin , dexrazoxane , ifosfamide , MESNA , etoposide , G-CSF ( PEG-filgrastim ) . The 3rd course consist ifosfamide , MESNA , etoposide , G-CSF ( PEG-filgrastrim ) . The total doxorubicin dose 450 mg/m2 . Patients poor response ( patient &lt; 90 % tumor necrosis find pathology time definitive resection ) receive five postoperative chemotherapy course . High Dose-Methotrexate administer 1st 3rd postoperative chemotherapy course 4-weekly 2-weekly dos , respectively . The 2nd course consist doxorubicin , dexrazoxane , cisplatin G-CSF ( PEG-filgrastim ) . The 4th course consist doxorubicin , dexrazoxane , ifosfamide , Mesna , etoposide , G-CSF ( PEG-filgrastim ) . The 5th cycle consist ifosfamide , Mesna , etoposide , G-CSF ( PEG-filgrastrim ) . The total doxorubicin dose 450 mg/m2 .</brief_summary>
	<brief_title>A Study Pre-Operative Treatment Newly-Diagnosed , Surgically-Resectable Osteosarcoma With Doxorubicin , Ifosfamide , Etoposide , Cisplatin With Early Metabolic Assessment Response</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<criteria>Must 2 35 year age time diagnosis Must biopsyproven , highgrade osteosarcoma . Patients metastasis eligible long lung site metastatic disease . The primary tumor pulmonary metastasis must deem potentially resectable . There must commitment surgical team resect primary tumor week 12 , pulmonary nodule point , unless clinical situation indicate intervention patient 's best interest . Patients must normal laboratory value cardiac function define : Creatinine clearance radioisotope GFR &gt; equal 70ml/min/1.73 m2 OR A serum creatinine base age/gender follow : Age Maximum Serum Creatinine ( mg/dL ) Male Female 1 month &lt; 6 month 0.4 0.4 6 month &lt; 1 year 0.5 0.5 1. &lt; 2 year 0.6 0.6 2. &lt; 6 year 0.8 0.8 6 &lt; 10 year 1 1 10 &lt; 13 year 1.2 1.2 13 &lt; 16 year 1.5 1.4 equal 16 year 1.7 1.4 Cardiac : Adequate cardiac function define : Shortening fraction &gt; equal 28 % echocardiogram OR Ejection fraction &gt; equal 50 % radionuclide angiogram Hepatic : Adequate liver function describe : Total bilirubin &lt; equal 1.5 x upper limit normal ( ULN ) age Hematologic function : adequate hematologic function define : ANC &gt; equal 1.5 x 10^9/L platelet count &gt; equal 100 x 10^9/L Female patient must negative pregnancy test Female patient lactate must agree stop breastfeeding . Patients must know HIV positive . Testing HIV mandatory . Sexually active patient childbearing potential must agree use effective contraception . Patients must able cooperate fully plan protocol therapy . Signed informed consent MUST obtain patient parent/legal guardian prior study procedure study entry . Patients lowgrade osteosarcoma , postradiation osteosarcoma , osteosarcoma associate Paget 's disease eligible . Patients metastases lung metastasis eligible . Patients may receive prior chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Osteosarcoma</keyword>
	<keyword>Surgically Resectable High Grade Osteosarcoma</keyword>
	<keyword>Lung Metastases Only</keyword>
</DOC>